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Gel phase phosphatidylcholineSifuvirtide, a 36 amino acid negatively charged peptide, is a novel HIV-1 fusion inhibitor with improved
antiretroviral activity. In this work we evaluated the physical chemistry foundation of the interaction of
sifuvirtide with biomembrane model systems. Since this peptide has aromatic residues, ﬂuorescence
spectroscopy techniques were mostly used. The interaction was assessed by partition and quenching
experiments. Results showed no signiﬁcant interaction with large unilamellar vesicles composed by
sphingomyelin and ceramide. In contrast, sifuvirtide presented selectivity towards vesicles composed by
phosphatidylcholines (PC) in the gel phase, in opposition to ﬂuid phase PC vesicles. The interaction of this
peptide with gel phase PC membranes (Kp=1.2×10
2) is dependent on the ionic strength, which indicates
the mediation of electrostatic interactions at an interfacial level. The effects of sifuvirtide on the lipid
membranes' structural properties were further evaluated using dipole-potential membrane probes, zeta-
potential, dynamic light scattering and atomic force microscopy measurements. The results show that
sifuvirtide does not cause a noticeable effect on lipid bilayer structure, except for membranes composed by
cationic phospholipids. Altogether, we can conclude that sifuvirtide presents a speciﬁc afﬁnity towards rigid
PC membranes, and the interaction is mediated by electrostatic factors, not affecting the membrane
architecture.+351 217999477.
anho).
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The human immunodeﬁciency virus type 1 (HIV-1) is the causa-
tive agent of the acquired immunodeﬁciency syndrome (AIDS). One of
the crucial steps of the HIV-1 infection cycle is the binding and entry
of the virus into the target CD4+ host cells, mediated by the viral
envelope proteins gp120 and gp41. After binding of the surface
protein gp120 to CD4 and CCR5 (or CXCR4) receptors, a cascade of
conformational changes on the transmembrane protein gp41 is trig-
gered. Following the exposure and insertion of the fusion peptide into
the target cell membrane, the two helical domains of gp41, N-terminal
and C-terminal heptad repeat (HR1 and HR2), are allowed to interact
and form a 6-helix bundle (a stabilized trimer of hairpins structure),
bringing in close proximity the viral envelope and cellular membrane
and thus enabling both membranes to fuse [1–3].
Inhibitors acting on the fusion process are one of the most novel
and promising anti-HIV therapies [3–6]. Synthetic peptides are being
developed based on the gp41 HR2 to target the viral HR1/HR2
interaction. Enfuvirtide (formerly T-20, the only FDA-approved drug
in this class) and T-1249 are two fusion inhibitor peptides presentinghigh therapeutic potency [3,5,6]. Nonetheless, the emergence of
undesired resistant strains of the virus and the natural side effects
due to a prolonged antiretroviral drug administration are common;
therefore, it is important to keep the development of more potent
drugs a top priority.
The development of new fusion inhibitors has been focused on the
improvement of the afﬁnity to the HR1 region of gp41 bymeans of the
increase in the helical content and stability of the peptides [7–11]. To
achieve this, most of the newly designed peptides include the deep
pocket binding domain essential for an improved anti-HIV activity
[12–14].
Besides the competitive binding to HR1, the interaction of fusion
inhibitors with biological membranes is important for their mode of
action and activity, since the inhibition process must occur in extreme
conﬁnement between both viral and cellular membranes [15]. For
instance it was shown that enfuvirtide [16] and T-1249 [17] interact
with lipid membranes. Enfuvirtide inserts preferentially in ﬂuid phase
lipid membranes, whereas T-1249 may also adsorb on the surface of
cholesterol-rich membranes. Membranes can therefore serve as
catalysts [18] of the inhibition process, by providing an increased
concentration of peptide near the fusion site.
Sifuvirtide is a novel HIV fusion inhibitor presently in phase II
clinical trials [19]. It possesses a higher activity and lower toxicity
when compared to enfuvirtide, proﬁling itself as a suitable and
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(Fig. 1) presents amphipathic segments, increased helicity, a global
negative net charge (−6) and two tryptophan amino acid residues,
rendering it suitable to be studied by ﬂuorescence spectroscopy
without the need of further labelling. We previously reported a
selective adsorption of this peptide on rigid dipalmitoylphosphati-
dylcholine (DPPC) membranes [23], which may help to explain its
improved efﬁciency by screening the more rigid domains of the
membrane. Nonetheless the nature of this interaction and the
dependence on rigid lipid composition, such as sphingomyelin (SM)
and ceramide (Cer), and also other saturated phosphatidylcholines
(PC), characteristic of lipid rafts and viral envelopes [24–27], are
still not fully understood. For instance, in HIV membranes there is a
3.2-fold increase in SM and a 3.6-fold increase in saturated PC
compared to eukaryotic plasmamembranes [24]. Due to the increased
concentration of these lipid components in the viral membrane and
lipid rafts, it is important to have a better insight on their afﬁnity with
HIV fusion inhibitors, especially in the case of sifuvirtide. The aim of
this work is, therefore, to study the interaction of sifuvirtide with rigid
membrane models, using mainly ﬂuorescence spectroscopy techni-
ques. Atomic force microscopy (AFM), dynamic light scattering (DLS)
and zeta-potential measurements were additionally used throughout
this work. Its ultimate goal is to clarify the speciﬁc molecular mode of
action of sifuvirtide at the membrane level, demonstrating the
importance of membrane interactions and interfacial properties of
lipids in the improved efﬁciency of sifuvirtide as a novel HIV fusion
inhibitor peptide.2. Materials and methods
2.1. Materials
Sifuvirtide, was a kind gift from FusoGen Pharmaceuticals Inc.
(Tianjin, P. R. China). 1-Palmitoyl-2-oleyl-sn-glycero-3-phosphocho-
line (POPC), 1-palmitoyl-2-oleyl-sn-glycero-3-ethylphosphocholine
(EPOPC), 1,2-dilauroyl-sn-glycero-3-phosphocholine (DLPC), 1,2-
dipalmitoyl-sn-glycero-3-phosphocholine (DPPC), 1,2-distearoyl-sn-
glycero-3-phosphocholine (DSPC), N-palmitoyl-D-erythro-sphingo-Fig. 1. (A) Amino acid sequence of HIV fusion inhibitor sifuvirtide. (B) Lateral and (C) frontal
in this arrangement are projected towards one side of the peptide helix. Hydrophobic residsine (C16 Ceramide, Cer) and chicken egg yolk sphingomyelin
(SM) were purchased from Avanti Polar Lipids (Alabaster, AL).
Cholesterol (Chol) was obtained from Sigma (St. Louis, MO),
whereas 1-anilinonaphthalene-8-sulfonic acid (ANS) and 4-[2-[6-
(dioctylamino)-2-naphthalenyl]ethenyl]-1-(3-sulfopropyl)-pyridi-
num (Di-8-ANEPPS) were purchased from Molecular Probes
(Eugene, OR). L-tryptophan (Trp), acrylamide, N-2-hydroxyethylpi-
perazine-N′-2-ethanesulfonic acid (HEPES), ethylenedinitrilotetraa-
cetic acid (EDTA), NaOH, NaCl, CaCl2·2H2O, chloroform and
methanol (both with spectroscopic grade) were purchased from
Merck (Darmstadt, Germany).2.2. Sample preparation and instrumentation
Sifuvirtide and Trp stock solutions were prepared in 10 mMHEPES
buffer pH 7.4, containing 10 mM or 150 mM NaCl (low or physiologic
ionic strength, respectively). Concentrated suspensions of large and
small unilamellar vesicles (LUV and SUV, respectively) were prepared
by extrusion or sonication methods, as described elsewhere [28,29].
Several lipid mixtures were used throughout this work. For
spectroscopy assays, LUV (prepared by extrusion through 100 nm
pore size ﬁlters) were used as models for biological membranes.
POPC, POPC:EPOPC (1:1), DLPC, DPPC, DSPC, SM, SM:Chol (2:1) and
SM:Cer (9:1 and 7:3) mixtures were mainly analyzed. For AFM
experiments, supported lipid bilayers were obtained by fusion of SUV
deposited on mica [30]. POPC:DPPC (1:1) and POPC:EPOPC:DPPC
(4:1:3) mixtures were chosen. All the experiments were performed at
22 °C, and, unless otherwise stated, all the solutions were prepared
using the same buffers as for the sifuvirtide and Trp stock solutions.
Absorption measurements were performed in a UV–vis spec-
trometer Jasco V-560 (Easton, MD), ﬂuorescence assays were carried
out in a Varian Cary Eclipse spectroﬂuorometer (Mulgrave, Aus-
tralia) and a Malvern Instruments Nano ZS (Worcestershire, UK) was
used for DLS and zeta-potential measurements. Disposable polysty-
rene and capillary cells were used in DLS and zeta-potential mea-
surements, respectively, whereas 0.5 cm length quartz cells were
used for adsorption and ﬂuorescence measurements. To perform
AFM experiments, a JPK Nanowizard II (Berlin, Germany) coupled toviews of sifuvirtide inα-helical arrangement. It should be noticed that charged residues
ues are represented in blue, noncharged polar in green, and charged polar in red.
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utilized.
2.3. Photophysical characterization of sifuvirtide in aqueous solution
Based on the presence of Trp residues on the sequence of
sifuvirtide, the spectral characteristics in aqueous and lipidic
environments of this peptide were studied by ﬂuorescence spectros-
copy at low and physiologic ionic strengths. Emission spectra were
collected in the 300–450 nm wavelength range, at an excitation
wavelength (λexc) of 280 nm. The dependence of the emission
ﬂuorescence intensity of sifuvirtide on its concentration was studied
in the 0.5–15 µM range. All the spectra were corrected for inner ﬁlter
effect [31]. Whenever a ﬁxed concentration of peptide was needed,
sifuvirtide 15 µM was used. In the case of the Trp solutions (used as
controls), a ﬁxed concentration of 36 µM was chosen. In both cases,
the absorbance of the solutions is below 0.1, ensuring minimal inner
ﬁlter effects [31]. The accessibility of the Trp residues in the peptide
structure was assessed by quenching assays using acrylamide, as
described in Section 2.5. The relative ﬂuorescence quantum yield for
sifuvirtide at both low and physiologic ionic strengths was deter-
mined as indicated in Ref. [32] by choosing a Trp solution as standard.
To study the effect of CaCl2 in the structural properties of sifuvirtide,
the ﬂuorescence emission spectra of the 15 µM peptidewere recorded
in the 0–10 mM CaCl2 concentration range in a 10 mM HEPES pH 7.4
150 mM NaCl buffer. To further complement the previous studies, the
ﬂuorescence of ANS 26 µM (λexc=344 nm; λem: [430,630 nm]) was
also evaluated at the same peptide and CaCl2 concentrations.
2.4. Membrane interaction studies
Membrane partition studies were carried by successive additions
of small amounts of 15 mM lipid suspensions (LUV) to a sifuvirtide
15 µM solution, with a 10 min incubation between each addition.
Samples were prepared in 10 mMHEPES buffer pH 7.4 with low (NaCl
10 mM) or physiologic (NaCl 150 mM) ionic strength, or in the
presence of CaCl2 at concentration ranging from 0 to 12.5 mM. The
membrane interactions were assessed by steady-state ﬂuorescence
(according to Ref. [33]), recording the emission in the 300–450 nm
range with an excitation wavelength of 280 nm. The ﬂuorescence
intensities were corrected for successive dilutions, background
intensities and scatter [34]. To study the effect of NaCl concentration
in the speciﬁc interaction of sifuvirtide with DPPC, the concentrations
of peptide and lipid were kept constant (15 µM and 3 mM,
respectively), varying the NaCl concentration from 0.01 M to 1 M by
adding small amounts of a 2.5 M concentrated NaCl to our samples.
2.5. Quenching experiments
Fluorescence quenching of sifuvirtide was assessed using the
quencher soluble in aqueous solution, acrylamide. The assays were
performed using sifuvirtide 15 μM in low or physiologic ionic strength
buffer, in the presence or absence of 3 mM of lipid (LUV). Small
aliquots of acrylamide were successively added to the samples. The
acrylamide concentrations were within the 0–60 mM range [23]. For
every addition a minimal 10 min incubation time was allowed before
measurement. To minimize the relative quencher/ﬂuorophore light-
adsorption ratios, the excitation wavelength used was 290 nm.
Regarding the emission, it was recorded at a ﬁxed wavelength of
360 nm. Quenching data were corrected both for inner ﬁlter effect and
light-adsorption [35], before being analyzed using the Stern–Volmer
equation [36] (Eq. (1)) or the Lehrer equation [37,38] (Eq. (2)), when
a negative deviation to the Stern–Volmer relationship is observed.
I0
I
= 1 + KSV Q½  ð1ÞI0
I
=
1 + KSV Q½ 
ð1 + KSV Q½  1−fBð Þ + fB
ð2Þ
I and I0 are the ﬂuorescence intensities of the sample in the
presence and absence of quencher, respectively, KSV is the Stern–
Volmer constant, [Q] the quencher concentration and fB is the fraction
of peptide accessible to the quencher. Additionally, when a fB value is
retrieved, an apparent partition coefﬁcient value, Kp, can be calculated
using Eq. (3):
Kp =
1−fB
fB
×
1
γL L½ 
; ð3Þ
valid for γL[L]≪1, where [L] is the lipid concentration and γL the
molar volume of a lipid bilayer [39].
2.6. Dipole potential membrane assays
Changes on the membrane dipole potential magnitude, driven by
membrane binding and insertion of the peptide, were monitored by
means of ﬂuorescence excitation spectral shifts of the dye di-8-
ANEPPS [40,41]. Small volumes of di-8-ANEPPS dissolved in ethanol
(less than 2%) [42] were added to LUV. To allow proper incorporation
of the probe within the membranes, the mixtures were incubated
overnight. For these assays, the ﬁnal concentrations used were
200 µM for lipids, 5 µM for di-8-ANEPPS and 15 µM for sifuvirtide
[43,44]. Fluorescence difference spectra of di-8-ANEPPS-labelled
vesicles were obtained by subtracting the excitation spectrum before
the addition of peptide from the excitation spectrum after the
addition of sifuvirtide 15 µM. Before subtraction, the spectra were
normalized to the integrated areas to reﬂect only the spectral shifts.
The emission wavelengths were ﬁxed at the maximum for each
vesicle composition used. All the experiments in this assay were
performed using a 10 mM HEPES buffer pH 7.4 in NaCl 150 mM.
2.7. Zeta-potential and dynamic light scattering spectroscopy (DLS)
DLS experiments [45–47] of lipid vesicles (LUV) in the presence of
peptidewere carried out with a backscattering detection at 173° using
an incident wavelength of 632.8 nm, at 25 °C, with an incubation time
of 15 min. Before measurements, the samples were ﬁltered with
0.45 µm pore nylon membranes (Whatman, Kent, UK). Lipid concen-
tration was ﬁxed at 50 or 200 μM and the sifuvirtide concentration
varied from 0 to 15 µM. Normalized intensity autocorrelation func-
tions were analyzed using the CONTIN method [48,49] yielding a
distribution of diffusion coefﬁcients (D) through multiexponential
ﬁts. Themeasured Dwas used for the calculation of the hydrodynamic
radius of the vesicles through the Stokes–Einstein relationship [50].
Zeta-potential experiments of lipid vesicles (LUV) in the presence
of peptide were based on the laser-Doppler electrophoresis [46,47].
The scattered light detection during zeta-potential measurementswas
made at the forward angle of 12°. Lipid concentration was ﬁxed at
200 μM and the sifuvirtide concentration varied from 0 to 40 µM. The
values of zeta-potential of the liposomes were calculated from their
electrophoretic mobility at 25 °C (15 min pre-incubation times) by
means of the Henry correction of Smoluchowski's equation [51,52].
Results are the average of 9 to 15measurements at the stationary level.
When signiﬁcant changes of the zeta-potential occurred as a function
of the peptide concentration, results were ﬁtted using Eq. (4):
ζ =
ζ0 + ζlimKB P½ 
1 + KB P½ 
ð4Þ
where ζ0 is the zeta-potential value of the vesicles in the absence of
peptide, ζlim corresponds to the zeta-potential value of the vesicles in
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concentration and KB the apparent binding constant.
All the samples at this study were prepared using a 10 mM HEPES
buffer pH 7.4 in NaCl 150 mM.
2.8. Atomic force microscopy (AFM)
AFM [53–55] was used to visualize the sifuvirtide-induced
topographical perturbations on phase separated supported lipid
bilayers. A 1.5 mM SUV suspension (10 mM HEPES buffer pH 7.4 in
NaCl 150 mM) was deposited in the presence of CaCl2 50 mM on a
freshly cleaved mica substrate previously glued to a glass coverslip.
The lipid sample was then incubated for 30 min at 25 °C. After
incubation, the sample was rinsed at least 4 times with EDTA 1 mM
and afterwards at least 10 times with buffer.
AFM imaging was performed using uncoated silicon cantilevers
CSC38 from MikroMasch (Tallinn, Estonia) with a typical spring
constant of 0.01–0.2 N/m for contact mode and uncoated silicon
nitride cantilevers OMCL-TR800PSA-1 from Olympus (Tokyo, Japan)
with a typical stiffness of 0.57 N/m for intermittent contact mode. The
scan rate was set to less than 1 Hz for intermittent contact mode and
between 1–2.5 Hz for contact mode. The force applied on the sample
was maintained at the lowest possible value by continuously
adjusting the set-point and gain during the imaging. For intermittent
contact mode the cantilever oscillation was turned to a frequency of
15–20 kHz. Height, deﬂection and phase-shift signals were collected
and images were line-ﬁtted as required. Tip artefacts were ruled out
by image analysis.
3. Results and discussion
3.1. Characterization of sifuvirtide in aqueous solution
Fluorescence spectra of sifuvirtidewere recorded in solution under
physiological pH and under low (NaCl 10 mM) and physiological
(NaCl 150 mM) ionic strength conditions. Structural properties of this
peptide can be retrieved from the spectral characteristics of its Trp
residues [36,56]. At a peptide concentration of 15 µM, the peptide
presented the same excitation and emission maximum at both ionic
strength conditions (Fig. S1). An approximate value of 0.07 was
recovered for the ﬂuorescence quantum yield (Φ) of the peptide
under both ionic strengths. The dependence of the ﬂuorescence
quantum yield on peptide concentration was studied at both ionic
strength conditions, to evaluate possible changes in the supramolec-
ular structure of sifuvirtide. No signiﬁcant deviations of linearity were
observed, indicating the absence of aggregation in the analyzed
concentration range (0–15 µM) (Fig. S1). Fluorescence quenching of
the Trp residues of the peptide by acrylamide was also studied at both
conditions to assess the accessibility of the ﬂuorophores. Linear Stern–
Volmer plots were obtained (Fig. S1), revealing that the Trp residues
are accessible to the quencher and therefore not inserted in
hydrophobic pockets [23].
Additionally, as a calcium-binding domain was identiﬁed on the
original HR2 sequence of gp41 from which sifuvirtide is derived
[57,58], the effect of Ca2+ ions on the supramolecular organization of
sifuvirtide was evaluated. We intended to evaluate if the peptide
could sequester Ca2+ ions, contributing to neutralize its global
negative net charge, promoting a putative aggregation of peptide
monomers. The emission spectra of sifuvirtide (under physiological
pH and ionic strength) were registered upon successive additions of
calcium chloride (0–10 mM). No signiﬁcant changes in the ﬂuores-
cence intensities neither spectral shifts were observed (data not
shown), providing evidence of no signiﬁcant aggregation. ANS was
also used as a reporter for supramolecular aggregation, since it is
conventionally considered to bind to pre-existing hydrophobic
(nonpolar) surfaces of proteins and peptides, being this bindingconcomitantly followed by an increase in its ﬂuorescence intensity
[56,59]. ANS emission spectra were recorded upon addition of calcium
chloride (0–10 mM) and no signiﬁcant increase of the ANS ﬂuores-
cence intensity was recovered (data not shown).
All these results suggest that the Trp residues of this peptide are
considerably exposed to the aqueous medium [36,56] and that the
ionic strength and Ca2+ concentration do not contribute signiﬁcantly
tomajormolecular changes on the supramolecular organization of the
peptide.
3.2. Interaction of sifuvirtide with rigid membrane models
Previous studies performed by our group revealed the importance
of lipid phase in the interaction of sifuvirtide with zwitterionic lipid
membrane models [23]. Sifuvirtide adsorbs on the surface of DPPC gel
phase (So) membranes, but does not interact signiﬁcantly, for
instance, with POPC liquid disordered (ld) or POPC:Chol liquid
ordered (lo) membranes. Lipid rafts [26], where the receptors needed
for HIV entry are located upon viral binding [27], and the viral
membrane [24,25] are enriched in rigid lipids such as sphingolipids
and saturated PC. Furthermore the speciﬁcity of the interaction of
sifuvirtide within these rigid membrane domains would be a key
factor for its improved efﬁcacy, since the inhibition process occurs in
extreme conﬁnement between those membranes [23]. Therefore, we
were prompted to study in more detail the interaction of sifuvirtide
with rigid bilayer vesicles of several lipid compositions.
The interaction of sifuvirtide (15 µM) with rigid membrane
models at physiological pH and ionic strength conditions was studied
using LUV of DPPC, DSPC, SM, SM:Chol (2:1) and SM:Cer (9:1 and
7:3). POPC and DLPC were used as liquid disordered membrane
models for the sake of comparison.
No signiﬁcant changes in the ﬂuorescence intensity (Fig. 2A) or
spectral shifts (data not shown) were observed for the ﬂuid phase
POPC and DLPC vesicles. Nonetheless, for the gel phase DPPC and DSPC
bilayers a signiﬁcant increase in the ﬂuorescence intensity (Fig. 2A), as
well a signiﬁcant blue-shift of the emission spectra (7 nm), was
observed. This indicates that sifuvirtide binds speciﬁcally to gel phase
PC bilayers, such as DPPC (gel-liquid phase transition temperature,
Tm=41.4±0.5 °C [60]) or DSPC (Tm=55.1±1.5 °C [60]), but not
towards PC with disaturated acyl chains presenting a ﬂuid phase
organization, such as DLPC (Tm=−1.1±0.8 °C [60]). It is to be
noticed that the addition of cholesterol and POPC to DPPC vesicles
would reduce the afﬁnity of sifuvirtide towards lipids [23].
Concerning the interaction of sifuvirtide with vesicles containing
sphingolipids, no signiﬁcant afﬁnity of the peptides toward these
membranes was observed. In the case of SM and SM:Cer, which
present similar or stronger gel phase properties at room temperature,
when compared to DPPC [61,62], no signiﬁcant changes in the
ﬂuorescence intensities (Fig. 2A) nor spectral-blue shifts (data not
shown) were observed. At this point, this would indicate that the
interaction of sifuvirtide with membranes is speciﬁc towards rigid PC
membranes.
To further elucidate and quantify this interaction, quenching
experiments in the presence of lipid vesicles, using acrylamide as a
quencher of the peptide's ﬂuorescence, were performed. Acrylamide
is a soluble quencher in aqueous solution that presents a low pene-
tration into lipid bilayers capacity [63]. If a peptide interacts with lipid
bilayers, it will be less accessible to the quencher in solution and
therefore its ﬂuorescence will be less quenched [64,65]. A character-
istic negative deviation to the linear Stern–Volmer relationship can
then be observed and, by ﬁtting the Lehrer equation to the data, it is
possible to obtain the fraction of peptide that is accessible to the
quencher in the solution (fB) [23], and subsequently the fraction of
peptide interacting with the lipid bilayers. In addition, a partition
coefﬁcient value (Kp) for this interaction can be calculated [33]. A
comparison of the quenching proﬁles in the presence and in the
Fig. 2. Sifuvirtide interaction with lipid membranes. (A) Titration of sifuvirtide 15 µM
with LUV. (B) Fluorescence quenching of sifuvirtide 15 µM in the presence of 3 mM
lipid vesicles. The dashed lines are ﬁttings of the Stern–Volmer equation (Eq. (1))
whereas the solid line is a ﬁtting of the Lehrer equation (Eq. (2)) to experimental data.
All the assays were performed in 10 mMHEPES buffer pH 7.4, containing NaCl 150 mM.
(I — ﬂuorescence intensity of sifuvirtide at 360 nm; I0 — ﬂuorescence intensity in the
absence of lipid (A) or acrylamide (B)).
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for all the studied lipid compositions, except DPPC, a linear quenching
proﬁle similar to the peptide in the absence of lipid was obtained.
Similar KSV values were obtained (Table 1). In the case of DPPC, a
negative deviation to the Stern–Volmer relationship was observed,
indicating that a fraction of peptide is interacting with those vesicles.
Applying the Lehrer equation, we could retrieve a value of fB=0.8,
similar to the value previously obtained by time-resolved ﬂuores-Table 1
Parameters obtained for the quenching of ﬂuorescence of sifuvirtide by acrylamide in
aqueous and lipidic environment.
KSV (M−1) fB
Aq. sol NaCl 150 mM 13.1±0.7 1§
NaCl 10 mM 13.3±0.3 1§
Lipid SM 12.8±0.3 1§
SM:Chol (2:1) 15.1±0.1 1§
SM:Cer (9:1) 11.8±0.2 1§
SM:Cer (7:3) 14.5±0.5 1§
DPPC 11.7±4.5 0.8±0.2#
Assays were performed in 10 mM HEPES buffer pH 7.4, containing 10 or 150 mM NaCl.
KSV and fB were obtained using Eqs. (1)§ and (2)#. All experiments with lipid were
conducted with 3 mM lipid concentration and 150 mM NaCl buffer.cence (fB=0.84). This yields a value of Kp=1.2×102, similar to the
one previously obtained using a Förster resonance energy transfer
approach (Kp=1.2×102) [23].
Altogether, the partition and quenching data indicate a selective
afﬁnity of sifuvirtide towards gel phase PC lipids, but not towards SM.
3.3. Effect of salt concentration on the interaction of sifuvirtide with
membranes
Salt concentration can affect both peptides and lipids. The increase
in the ionic strength affects the Debye screening length, diminishing
for instance the electrostatic repulsion among charged peptide
molecules or, in the case of neutral lipids, the repulsive forces between
the polar parts of lipid molecules [66]. Furthermore, the dependence
on the salt concentration can give us valuable information about the
electrostatic or non-electrostatic nature of peptide–lipid interactions.
Since sifuvirtide presented a selective afﬁnity towards gel phase PC
membranes, we were prompted to study the effect of ionic strength
in the interaction of sifuvirtide with DPPC vesicles. We studied the
effect of NaCl salt concentration on the interaction of sifuvirtide with
DPPC vesicles. A signiﬁcant decrease in the ﬂuorescence intensity of
sifuvirtide in the presence of DPPC vesicles at [NaCl]=10 mM, when
compared to [NaCl]=150 mM, was observed (Fig. 3A). At physiolog-
ical ionic strength, the increase in the ﬂuorescence intensities was
concomitant with a blue-shift of the emission spectra. In contrast, atFig. 3. Effect of ionic strength in the interaction of sifuvirtide with DPPC vesicles.
(A) Titration of sifuvirtide 15 µM with DPPC LUV under different ionic strengths.
(B) Interactionof sifuvirtide15 µMwithDPPCandPOPCvesicles (3 mMlipid concentration)
as a function of the concentration of NaCl. (I — ﬂuorescence intensity of sifuvirtide at
360 nm; I0 — ﬂuorescence intensity in the absence of lipid (A) or at 10 mM NaCl (B)).
Fig. 4.Dipole membrane-dependent differential excitation ﬂuorescence spectra of di-8-
ANEPPS-labelled vesicles in the presence of sifuvirtide 15 µM. Lipid concentration and
di-8-ANEPPS were kept constant at 200 µM and 5 µM, respectively. All the assays were
performed in 10 mM HEPES buffer pH 7.4, containing NaCl 150 mM.
Fig. 5. Zeta-potential dependence of LUV on sifuvirtide concentration. Lipid concen-
tration was kept constant at 200 µM. Each point corresponds to an average of 9–15
measurements. Error bars represent standard deviation. Solid line is the ﬁtting of
Eq. (4) to POPC:EPOPC (1:1) data. Dashed line corresponds to the zeta-potential value
of 560 µM sifuvirtide. All the assays were performed in 10 mM HEPES buffer pH 7.4,
containing NaCl 150 mM.
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intensity or blue-shifts were observed.
The ﬂuorescence intensity of sifuvirtide in the presence of DPPC
and POPC membranes was measured in the NaCl concentration range
10 mM–1 M (Fig. 3B). POPC served as an initial negative control in this
experiment, since there is no interaction of the peptide with this lipid.
For POPC no signiﬁcant changes in ﬂuorescence parameterswithin the
analyzed NaCl concentration range occurred. For DPPC, between 10
and 50 mM of NaCl, no signiﬁcant changes in the peptide's
ﬂuorescence emission intensity or spectrum were observed. For salt
concentrations in the 50–300 mM range, a signiﬁcant increase in the
ﬂuorescence intensity of the peptide, accompanied by a signiﬁcant
blue-shift of the emission spectra is observed. At higher concentra-
tion, a lower increase in the ﬂuorescence intensities and emission
blue-shift were obtained.
Besides the effect of Na+, we assessed the effect of Ca2+ ions on the
interaction of sifuvirtide with POPC and DPPC LUV. For the ﬂuid phase
POPC vesicles, as expected, the addition of CaCl2 did not cause any
signiﬁcant increase in the ﬂuorescence intensity of the peptide
(Fig. S2) nor spectral shifts (data not shown). Nevertheless, in the
case of the gel phase DPPC vesicles, small increases in the ﬂuorescence
intensity of the peptide were observed as the calcium chloride con-
centration was increased (Fig. S2).
Since the afﬁnity of sifuvirtide towards DPPC gel phasemembranes
is affected by the ionic strength, the results obtained indicate a depen-
dence on electrostatic factors. The nature of this interaction should be
related to interfacial speciﬁcities of rigid PC membranes at high salt
concentrations, more precisely at the choline headgroup level [67,68].
3.4. Evaluation of the membrane dipole-potential of lipid bilayers upon
interaction with sifuvirtide
The use of intrinsic ﬂuorescence properties of a peptide to evaluate
its interaction with lipid bilayers is important to determine structure,
dynamics and locationwithin themembranes [36,56]. However, instead
of focusing the measurements on the peptide, changes in membrane
properties can also serve as a valuable sensor in peptide–lipid inter-
actions [40]. Thus, to further elucidate the action of sifuvirtide at the
membrane level, we studied changes in themembrane dipole potential
and zeta-potential, as well as the aggregation susceptibility of the lipid
vesicles upon addition of peptide.
Themembrane dipole potential is originated from the alignment of
dipolar residues of lipids (polar headgroups and glycerol-ester
regions) and oriented water molecules hydrating the outer surface
of the membrane [40,41]. The magnitude of the membrane dipole is
affected by membrane binding and by the insertion or adsorption of
molecules (including peptides) [43,69]. Changes on the dipole
potential magnitude may be monitored through spectral shifts of
the ﬂuorescence dye di-8-ANEPPS, sensing the local electric ﬁeld
derived from the dipoles of the lipid headgroup region [40,41]. No
signiﬁcant spectral shifts promoted by the peptide occur in POPC
(Fig. 4), POPC:Chol (2:1) and SM (data not shown). The exceptions are
DPPC and POPC:EPOPC vesicles (positive control) (Fig. 4), that
presented spectral shifts to the red indicative of decreases in the
dipole potential. Sifuvirtide interacts strongly with vesicles containing
EPOPC and this peptide inserts into these membranes due to
electrostatic attraction of the negatively charged sifuvirtide towards
the EPOPC cationic headgroups [23]. In the case of DPPC vesicles, only
a slight decrease of the membrane dipole potential was recovered, in
accordance with the very low Kp previously estimated.
3.5. Evaluation of the zeta-potential and dynamic light scattering (DLS)
parameters of lipid bilayers upon interaction with sifuvirtide
The zeta-potential of a particle is related to its surface charge
potential, corresponding to the potential at the hydrodynamic shearsurface [51,52]. This potential can be calculated by the electrophoretic
mobility of the particles in solution by laser-Doppler velocimetry in a
zeta-sizer device [46]. First of all, we evaluated the mean zeta-
potential value (ζ) of a concentrated solution of sifuvirtide (560 µM)
under physiological pH and ionic strength. In agreement with the
negative charge of the peptide, we found ζ=−12.6±2.4 mV. ζ values
for POPC:EPOPC, POPC and DPPC vesicles (200 µM lipid concentra-
tion) in the presence of several concentration of peptide (0–40 µM)
were measured under the same conditions (Fig. 5). Upon addition of
increasing concentrations of peptide, no extensive changes in the ζ
values in DPPC and POPC vesicles were recovered. This is expected for
POPC, but in the case of DPPC vesicles these results could indicate a
desorption of the peptide during the electrophoretic process. In
contrast, we obtained a signiﬁcant decrease in the zeta-potential upon
addition of peptide to vesicles containing EPOPC that we could ﬁt
using Eq. (4), obtaining an apparent binding coefﬁcient (KB) of (2.0±
0.8)×102 mM−1. It should be noticed that this value does not have
direct correspondence to the partition constant values, determined by
ﬂuorescence spectroscopy. Furthermore, regarding the zeta-potential
of those vesicles at saturating peptide concentrations (ζlim), we
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reaching electroneutrality.
DLS [46] of POPC:EPOPC vesicles at 200 µM lipid concentration and
in the presence and absence of 15 µM sifuvirtide, reveals an increase
in the hydrodynamic radius of the vesicles in the presence of the
peptide (data not shown), possibly due to the initiation of the
aggregation of the POPC:EPOPC vesicles. Zeta-potential values in these
conditions show that almost all the positive charges on the EPOPC
moieties are being neutralized by the negatively charged peptide, and
therefore electroneutrality is being reached. At low peptide concen-
trations no changes in the vesicles hydrodynamic radius were de-
tected.We also tested the aggregation tendency of DPPC vesicles upon
addition of peptide and no signiﬁcant changes of the hydrodynamic
radius of the vesicles were retrieved (as seen for POPC). The
hydrodynamic radius of DPPC vesicles remained constant regardless
of peptide concentration. Altogether, the results show that sifuvirtide
does not cause a noticeable effect on lipid bilayer structure in DPPC
vesicles.
3.6. Evaluation of membrane topography upon interaction with
sifuvirtide by atomic force microscopy (AFM)
Given the selectivity of sifuvirtide to rigid membranes and its
ability to adsorb to bilayers without extensive perturbation, we were
interested in visualizing the effect of sifuvirtide on the topography
and stability of phase separated planar lipid bilayers. AFM was used
for this purpose. This technique uses a sharp tip to scan over a surface,
being the signal detected through an optic lever mechanism, enabling
the acquisition of high-resolution images [53]. It is to be noticed that
this technique was successfully applied in the study of the fusion
activity of the HIV gp41 ectodomain on lipid bilayers [70–72].Fig. 6. Effect of sifuvirtide on the topography of zwitterionic supported lipid bilayers with pha
the absence and in the presence of sifuvirtide 15 µM. Control measurements were perform
mode prior and after addition of peptide. 10 mM HEPES buffer pH 7.4 containing NaCl 150 m
whereas the darker parts correspond to the POPC ﬂuid phase.In this part of the work, POPC:DPPC (1:1) and POPC:EPOPC:DPPC
(4:1:3) lipid bilayers were imaged before and after the incubation
with sifuvirtide 15 µM. Controls adding buffer instead of peptide
solution were performed with the same incubation times and mea-
surement conditions. The peptide does not cause signiﬁcant changes
on the overall POPC:DPPC membrane topography (Fig. 6), which is
in agreement with the results obtained in the zeta-potential and
membrane dipole potential measurements. AFM, therefore, reinforces
the conclusion that the low but speciﬁc afﬁnity of sifuvirtide towards
DPPC (reported by ﬂuorescence spectroscopy) does not signiﬁcantly
perturb the surface of these membranes. In contrast, in the POPC:
EPOPC:DPPC (4:3:1) membrane system (Fig. 7), upon addition of
peptide and after a 2 h incubation, small defects spread over the
membrane in the ﬂuid matrix were observed. These defects, typically
less than 1–2 nm in depth, were not as deep as a hole in the lipid
bilayer (4–6 nm). Therefore, they can be interpreted as a local thin-
ning or partial disruption of the membrane matrix, most likely
involving the EPOPC cationic phospholipids, caused by the action of
the anionic peptide. Similar defects were reported in the action of an
amylin peptide in ﬂuid anionic lipid bilayers [73], for instance.
4. Conclusions
Sifuvirtide is a second generation HIV fusion inhibitor peptide with
an improved efﬁcacy and promising preclinical results [19,20,22]. It
was previously revealed that lipid membranes play an important role
in the mode of action of sifuvirtide and other HIV fusion inhibitors,
such as enfuvirtide and T-1249 [16,17,23,74,75]. Since the inhibition
of the membrane fusion process must occur in extreme conﬁnement
between the cellular plasma and viral membranes, the lipid bilayers
may be enhancers of the process (sometimes referred to as a catalytic-se separation. AFMmeasurements on POPC:DPPC (1:1) lipid bilayers were performed in
ed by adding buffer instead of peptide. Images were recovered at intermittent contact
M was used. The brighter (and higher) domains correspond to the DPPC rigid domains,
Fig. 7. Effect of sifuvirtide 15 µM on the topography of POPC:EPOPC:DPPC (4:1:3)
supported lipid bilayers after a 2 h incubation. Image obtained in contact mode in a
10 mM HEPES buffer pH 7.4, containing NaCl 150 mM. The brighter (higher) domains
correspond to the DPPC rigid domains, whereas the darker parts correspond to the
POPC:EPOPC ﬂuid matrix. (B) Height proﬁle of the cross-section (in grey) presented in
(A). As seen in (A) and (B), the presence of small defects (less than 1 nm in height) on
the lipid bilayer ﬂuid matrix caused by the peptide is to be noticed.
Fig. 8. Schematic representation of a putative mode of action of sifuvirtide on the
surface of DPPC gel phase membranes in the presence of high NaCl concentration. Na+
cations stabilize the anionic charge of the phosphatemoiety (red) in the PC headgroups,
leaving the choline moieties (cationic — blue) more exposed. This enables the anionic
peptide to adsorb on the membrane with its charged residues (blue— cationic residues,
red — anionic residues) oriented towards the surface, leaving the Trp residues (green)
in a more exposed and less protected orientation.
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fusion sites. Besides the interaction of enfuvirtide, T-1249 and
sifuvirtide with membranes, the interaction of peptides such as P1
(gp41 residues 649-683) and P5 (628-683) derived from the gp41
CHR with galactosylceramide (GalCer) in biological membranes was
also reported [57,58,76,77]. Furthermore, fusion inhibitors linked to
lipids and sterols to improve the afﬁnity to biological membranes
have increased anti-HIV activity, further demonstrating the impor-
tance of biological membranes in the mechanism of action of these
drugs [78,79]. Nevertheless, the interaction with membranes may
differ depending on the structural properties of the peptides. Com-
pared with the sequence of enfuvirtide, sifuvirtide has the deep
pocket binding domain [19], but lacks the Trp-rich domains of the
membrane proximal region (MPR) region of HIV gp41, which is as-
sumed to be important for the interaction with membranes [19]. In
opposition to sifuvirtide, enfuvirtide interacts strongly with POPC
vesicles and this may be due to the Trp-rich region in enfuvirtide's
C-terminus. On the other hand, sifuvirtide is able to adsorb at the
surface of DPPC gel phase membranes [23]. These structural dif-
ferences may be responsible for the distinct and more selective
mode of action of sifuvirtide. In this work, we revealed a unique se-
lectivity of sifuvirtide towards PC gel phase lipids. We demonstrated
that this peptide would interact with DPPC and DSPC gel phase
membranes, but not to SM or SM:Cer rigid membranes. Despite
having a low Kp, sifuvirtide is remarkably efﬁcient in screening rigidPC lipid bilayers. Nonetheless, no signiﬁcant changes on the mem-
brane dipole potential, zeta-potential and membrane topography
were reported for DPPC. This is indicative of a selective yet weak
adsorption on the surface of DPPC. An insertion into the membrane
would promote larger effects over these parameters, as seen for the
POPC:EPOPC controls. We can therefore hypothesize a low toxicity
of this peptide towards its targeted membranes, which may be
clinically important.
The selectively towards rigid PC membranes in contrast with SM,
may be explained by the interfacial differences that both membranes
present. Although both SM and PC contain a phosphocholine as the
polar headgroup, their hydrophobic backbone is different. Whereas
SM contains both hydrogen bond donating and accepting groups (due
to the sphingosine backbone), PC only has hydrogen bond accepting
groups [61]. These differences at the interfacial level do not affect
extensively the rigidity of both membranes (DPPC and 16:0-SM have
similar Tm [60]), but have a pronounced effect on the polarity, water
exposure and accessibility to salt at the headgroup level.
Moreover, for PC vesicles the conformation of the polar head-
groups depends on the binding of cations to the phosphate group [66].
Binding of positively charged solutes can repel the N+-end of the
choline moiety toward the aqueous phase [66]. According to a model
for the gel phase PC membrane [67], the conﬁguration of the polar
heads depends on the ionic strength. With the increase in salt
concentration, a rising number of standing polar heads was revealed,
exposing the choline moieties and increasing the accessibility of ions
and solutes [67]. This explains the dependence of the interaction of
sifuvirtide with DPPC vesicles on the ionic strength observed in this
work. At higher salt concentrations, the negatively charged sifuvirtide
is likely to bind to the positively charged choline moieties, closely
arranged and fully exposed at the surfaces of tightly packed PC
bilayers. This tendency to selectively interact with rigid PC mem-
branes is not limited to this peptide. Aβ peptides, for instance, interact
preferentially towards gel phase PC membranes [80–82].
Additionally to Na+ ions, Ca2+ ions can also contribute to improve
the interaction of sifuvirtide with membranes. Ca2+ cations are
important in the HIV membrane fusion process: 1) Ca2+ was reported
to be essential for post-binding steps of the fusion process [83,84];
and 2) a calcium-binding site was identiﬁed in gp41 CHR [57,58].
Sifuvirtide is not extensively affected by the presence of Ca2+ in the
solution and no aggregation was observed. Moreover, the presence of
high concentrations of Ca2+ slightly improved the interaction with
DPPC vesicles. This may be due to a bridging by Ca2+ between the
phosphate headgroups and the negative charges of the peptide [85].
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sifuvirtide towards PC gel membranes and unravels the molecular
basis of such selectivity. By complementing the results here presented
with those from the FRET experiment, where we validated the
hypothesis of the adsorption of sifuvirtide on the surface of DPPC
bilayers [23], we disclose a putative mode of action for this peptide on
PC gel phase membranes at physiological salt concentrations (Fig. 8
and Appendix B — Supporting information). The interaction of
sifuvirtide through its charged residues with gel phase PCmembranes
would explain the interplanar distances obtained by FRET in Ref. [23],
the higher values of interaction at higher ionic strengths and the low
Kp values for the partition of sifuvirtide in gel phase PC vesicles.
From a biological point of view, since saturated PC lipids are found
in high concentration in lipid rafts [26,27], but mainly in the viral
envelope (for instance DPPC represents approximately 20% of the PC
content in the viral membrane) [24,25], the efﬁcacy of sifuvirtide may
be related to its screening ability towards both these regions, allowing
the peptide to have an increased concentration at the fusion site.
Furthermore, several glycolipids and proteins are associated within
lipid rafts and viral membranes; thus, we can expect more possi-
bilities for transient electrostatic peptide–lipid and/or peptide–
protein interactions on the surface of those lipid domains. In the
end, the importance of membrane rigidity and selective electrostatic
interactions were demonstrated for the mode of action of sifuvirtide
at themolecular level andmay help the understanding of its improved
efﬁcacy when compared with other drugs from the same class.
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